Interpace Biosciences Inc Net debt/EBITDA
What is the Net debt/EBITDA of Interpace Biosciences Inc?
The Net debt/EBITDA of Interpace Biosciences Inc is -1.57
What is the definition of Net debt/EBITDA?
The net debt to earnings before interest, taxes, depreciation, and amortization (Net debt/EBITDA) ratio measures financial leverage and the company’s ability to pay off its debt. It shows how long it would take the company to pay off all its debt with operations at the current level.
The net debt to EBITDA ratio is calculated as Net debt divided by EBITDA. It is similar to the debt to EBITDA ratio, but cash and cash equivalents are subtracted in net debt.
Net debt = short-term debt + long-term debt - cash and cash equivalents
EBITDA = net income + interest expense + taxes + depreciation + amortization
Lower debt debt to EBITDA ratio indicates the company is not heavily indebted and should be able to repay its obligations. Alternatively, higher ratio indicated the company is excessively indebted. The ratio varies between industries as different industries have different capital requirements. Usually, the ratio should be compared to a benchmark or an industry average to determine the company’s credit risk. Generally, a net debt to EBITDA ratio above 4 or 5 is considered high.
Net debt/EBITDA of companies in the Health Care sector on NASDAQ compared to Interpace Biosciences Inc
What does Interpace Biosciences Inc do?
advancing patient care through molecular diagnostic testing. interpace diagnostics develops molecular diagnostic tests. our molecular diagnostic tests provide unparalleled accuracy and clarity to improve outcomes in patients facing a cancer diagnosis. you can be assured that all of the molecular tests we offer are driven by rigorous, validated science. we power the future of molecular diagnostics, delivering cutting-edge and much-needed mutational analysis that helps risk-stratify for thyroid, pancreatic, and other cancers to better inform treatment decisions. the unique molecular diagnostic tests we offer enable healthcare providers to avoid unnecessary surgeries and better assess the risk of cancer progression in their patients.
Companies with net debt/ebitda similar to Interpace Biosciences Inc
- Athabasca Oil has Net debt/EBITDA of -1.59
- Limbach Inc has Net debt/EBITDA of -1.58
- Batero Gold has Net debt/EBITDA of -1.58
- MGC Pharmaceuticals has Net debt/EBITDA of -1.58
- QS has Net debt/EBITDA of -1.58
- Simply has Net debt/EBITDA of -1.58
- Interpace Biosciences Inc has Net debt/EBITDA of -1.57
- Super Micro Computer Inc has Net debt/EBITDA of -1.57
- NexgenRx has Net debt/EBITDA of -1.57
- PostNL N.V has Net debt/EBITDA of -1.56
- Magontec has Net debt/EBITDA of -1.56
- Metalla Royalty & Streaming has Net debt/EBITDA of -1.55
- Invo Bioscience Inc has Net debt/EBITDA of -1.55